Benjamin F. Edwards & Company’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Benjamin F. Edwards & Company’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-150	Closed	-$5K	–	1218
2015 Q1	$5K	Hold	150	–	–	﹤0.01%	1006
2014 Q4	$6K	Hold	150	–	–	﹤0.01%	884
2014 Q3	$4K	Hold	150	–	–	﹤0.01%	893
2014 Q2	$4K	Hold	150	–	–	﹤0.01%	850
2014 Q1	$6K	Hold	150	–	–	﹤0.01%	765
2013 Q4	$6K	Buy	+150	New	+$5.87K	﹤0.01%	739

Other funds holding NAVB

Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return

Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Benjamin F. Edwards & Company's NAVB Position: Q2 2015 in Review

Benjamin F. Edwards & Company sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2015, closing a stake of 150 shares — an estimated $5K sold.

Benjamin F. Edwards & Company first reported a position in NAVB in Q4 2013 and held it in 6 quarters. The position peaked at $6K in Q4 2014. 79 funds tracked by Wall St. Rank hold NAVB as of Q2 2015.

Benjamin F. Edwards & Company reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2015 after selling out during the quarter.
Benjamin F. Edwards & Company sold 150 Navidea Biopharmaceuticals Inc. shares in Q2 2015, an estimated $5K.
Benjamin F. Edwards & Company first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2013 and held it in 6 quarters.
Benjamin F. Edwards & Company's Navidea Biopharmaceuticals Inc. position peaked at $6K in Q4 2014.
79 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2015.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2015, filed 10 Jul 2015.